|
|
xiii | |
About the editors |
|
xix | |
Preface |
|
xxiii | |
|
1 Microbial bioprocesses for production of nutraceuticals and functional foods |
|
|
1 | (30) |
|
|
|
|
|
|
1 | (1) |
|
1.2 Microbial production of nutraceuticals and functional foods |
|
|
2 | (14) |
|
1.3 Conclusions and perspectives |
|
|
16 | (15) |
|
|
16 | (15) |
|
2 Microbial transformation for improving food functionality |
|
|
31 | (16) |
|
|
|
2.1 Microbes and food production over the centuries |
|
|
31 | (2) |
|
2.2 Bioactive compounds as functional food ingredients |
|
|
33 | (1) |
|
2.3 Health-promoting bioactive compounds synthesized via microbial transformation |
|
|
34 | (4) |
|
2.4 Trends in the delivery of bioactive compounds targeting enhanced food functionality |
|
|
38 | (2) |
|
2.5 Fermented food as potential for antiviral therapy |
|
|
40 | (1) |
|
2.6 Conclusions and perspectives |
|
|
41 | (6) |
|
|
41 | (6) |
|
3 Bioactive peptide production in fermented foods |
|
|
47 | (26) |
|
|
|
|
|
|
Claucia Fernanda Volken De Souza |
|
|
|
47 | (1) |
|
3.2 Bioactive peptides in fermented dairy products |
|
|
48 | (4) |
|
3.3 Bioactive peptides in fermented meat products |
|
|
52 | (3) |
|
3.4 Bioactive peptides in fermented vegetables |
|
|
55 | (2) |
|
3.5 Biotechnological progress for industrial production of bioactive peptides |
|
|
57 | (5) |
|
3.6 Conclusions and perspectives |
|
|
62 | (11) |
|
|
63 | (10) |
|
4 Probiotics in fermented products and supplements |
|
|
73 | (36) |
|
|
|
|
|
|
|
|
|
|
73 | (1) |
|
|
74 | (6) |
|
4.3 Probiotics in fermented foods |
|
|
80 | (6) |
|
4.4 Interactions between probiotics and components of fermented foods |
|
|
86 | (1) |
|
4.5 Impact of probiotics on the human gut microbiome |
|
|
87 | (3) |
|
4.6 Ethnic fermented probiotics products translated to industry and their advantages over nonfermented products |
|
|
90 | (2) |
|
4.7 Challenges in the probiotics industry and future prospects |
|
|
92 | (3) |
|
4.8 Conclusions and perspectives |
|
|
95 | (14) |
|
|
95 | (1) |
|
|
96 | (13) |
|
5 Fructooligosaccharides production and the health benefits of prebiotics |
|
|
109 | (30) |
|
|
|
|
|
|
|
109 | (1) |
|
5.2 Fructans occurrence, chemical structure, technological properties, and market |
|
|
110 | (2) |
|
5.3 Fructooligosaccharides production |
|
|
112 | (8) |
|
5.4 Role of prebiotics in control of human diseases |
|
|
120 | (7) |
|
5.5 Conclusions and perspectives |
|
|
127 | (12) |
|
|
128 | (1) |
|
|
128 | (11) |
|
6 Production of food enzymes |
|
|
139 | (18) |
|
|
|
|
|
139 | (2) |
|
6.2 Applications of food enzymes in food industry |
|
|
141 | (3) |
|
6.3 Current progress and challenges in food enzymes production |
|
|
144 | (3) |
|
6.4 Advanced technologies for food enzymes production |
|
|
147 | (4) |
|
6.5 Conclusions and perspectives |
|
|
151 | (6) |
|
|
151 | (6) |
|
7 Production of fibrinolytic enzymes during food production |
|
|
157 | (32) |
|
|
Sri Charan Bindu Bavisetty |
|
|
|
|
|
|
|
157 | (1) |
|
7.2 Mechanism of blood clotting and fibrinogenesis |
|
|
158 | (1) |
|
7.3 Mechanism of action of FEs: fibrinolysis and thrombolysis |
|
|
159 | (1) |
|
7.4 Classification of FEs |
|
|
160 | (1) |
|
|
160 | (1) |
|
7.6 Biochemical characterization of FEs |
|
|
161 | (2) |
|
|
163 | (7) |
|
|
170 | (4) |
|
|
174 | (3) |
|
7.10 Conclusions and perspectives |
|
|
177 | (12) |
|
|
177 | (12) |
|
8 Microbial production and transformation of polyphenols |
|
|
189 | (20) |
|
|
|
|
|
|
|
189 | (1) |
|
8.2 Types of polyphenols and their health benefits |
|
|
190 | (2) |
|
8.3 Microbial production and enhancement of polyphenols during fermentation |
|
|
192 | (8) |
|
8.4 Effect of gut microbes on polyphenols |
|
|
200 | (1) |
|
8.5 Conclusions and perspectives |
|
|
200 | (9) |
|
|
201 | (8) |
|
9 Bioprocess technologies for production of structured lipids as nutraceuticals |
|
|
209 | (30) |
|
|
|
|
|
209 | (1) |
|
9.2 General aspects of lipids: definition, structure, and properties |
|
|
210 | (3) |
|
9.3 The role of lipids in human nutrition |
|
|
213 | (2) |
|
9.4 Production of structured lipids |
|
|
215 | (15) |
|
9.5 Conclusions and perspectives |
|
|
230 | (9) |
|
|
230 | (9) |
|
|
231 | (8) |
|
10 Microbial fermentation for reduction of antinutritional factors |
|
|
239 | (22) |
|
|
|
|
239 | (1) |
|
10.2 Nutritive and antinutritive properties in food |
|
|
240 | (8) |
|
10.3 Neutralizing antinutritional factors in fermented foods |
|
|
248 | (6) |
|
10.4 Conclusions and perspectives |
|
|
254 | (7) |
|
|
255 | (6) |
|
11 Mycotoxins in foods: impact on health |
|
|
261 | (12) |
|
Samuel Ayofemi Olalekan Adeyeye |
|
|
|
261 | (1) |
|
|
262 | (2) |
|
11.3 Mycotoxins in foods: impact on health |
|
|
264 | (2) |
|
11.4 Economic implications of mycotoxins in foods |
|
|
266 | (1) |
|
11.5 Mitigation and control of mycotoxins in foods |
|
|
266 | (2) |
|
11.6 Conclusions and perspectives |
|
|
268 | (5) |
|
|
269 | (4) |
|
12 Gut microbes: Role in production of nutraceuticals |
|
|
273 | (28) |
|
Palanisamy Athiyaman Balakumaran |
|
|
|
|
|
|
|
273 | (1) |
|
12.2 Role of the gut microbiome in human health |
|
|
274 | (2) |
|
12.3 Nutraceuticals and gut microbes |
|
|
276 | (1) |
|
12.4 Nutrigenomics: Gut microbes and health benefits |
|
|
276 | (2) |
|
12.5 Developments in nutraceuticals production using gut microbes |
|
|
278 | (1) |
|
12.6 Microbial strategies for the production of nutraceuticals |
|
|
279 | (1) |
|
12.7 Production of gamma-aminobutyric acid and hyaluronic acid by lactic acid bacteria |
|
|
279 | (1) |
|
12.8 Vitamin B12 and folate production by Propionibacteria |
|
|
280 | (1) |
|
12.9 Nutraceuticals production by Bacillus subtilis |
|
|
281 | (1) |
|
12.10 Glutathione, carotenoids, and other nutraceuticals production by yeasts |
|
|
281 | (1) |
|
12.11 Metabolic engineering of microbes for the production of nutraceuticals |
|
|
282 | (5) |
|
12.12 Market trends in the production of nutraceuticals |
|
|
287 | (1) |
|
12.13 Conclusions and perspectives |
|
|
288 | (13) |
|
|
289 | (1) |
|
|
289 | (12) |
|
13 Bioprocessing of agri-food processing residues into nutraceuticals and bioproducts |
|
|
301 | (22) |
|
|
|
|
|
|
|
|
|
301 | (2) |
|
13.2 Agri-food processing residues and valorization |
|
|
303 | (11) |
|
13.3 Conclusions and perspectives |
|
|
314 | (9) |
|
|
314 | (1) |
|
|
314 | (9) |
|
14 Genetically modified microorganisms for enhancing nutritional properties of food |
|
|
323 | (14) |
|
|
|
|
323 | (1) |
|
14.2 Techniques used for genetic modification |
|
|
324 | (1) |
|
14.3 Advantages of genetic modification |
|
|
324 | (1) |
|
14.4 Need for genetically modified food products |
|
|
324 | (1) |
|
14.5 Microorganisms as source of food enzymes |
|
|
325 | (1) |
|
14.6 Use of genetically modified microbes in food industry |
|
|
325 | (2) |
|
14.7 Characteristics of genetically modified microorganisms |
|
|
327 | (3) |
|
14.8 Products development using genetically modified microorganisms in food industry |
|
|
330 | (2) |
|
14.9 Fermented food products and their health benefits |
|
|
332 | (1) |
|
14.10 Conclusions and perspectives |
|
|
333 | (4) |
|
|
334 | (3) |
|
15 Exopolysaccharide producing microorganisms for functional food industry |
|
|
337 | (18) |
|
|
|
|
|
337 | (1) |
|
|
338 | (1) |
|
15.3 Important exopolysaccharides producing bacterial genera |
|
|
339 | (6) |
|
15.4 Fermented food containing exopolysaccharides |
|
|
345 | (2) |
|
15.5 Technological advantages of exopolysaccharides |
|
|
347 | (1) |
|
15.6 Health benefits of exopolysaccharides |
|
|
347 | (2) |
|
15.7 Conclusions and perspectives |
|
|
349 | (6) |
|
|
349 | (1) |
|
|
349 | (5) |
|
|
354 | (1) |
|
16 Microbial metabolites beneficial in regulation of obesity |
|
|
355 | (22) |
|
|
|
|
355 | (1) |
|
16.2 Composition of gut microbiota |
|
|
356 | (1) |
|
16.3 Obesity and lipid metabolism |
|
|
357 | (1) |
|
|
358 | (1) |
|
16.5 Antilipid effect of Cineromycin B |
|
|
359 | (1) |
|
|
359 | (1) |
|
16.7 Short-chain fatty acids |
|
|
360 | (2) |
|
16.8 New players for obesity treatment |
|
|
362 | (2) |
|
16.9 Orlistat: Food and Drug Administration-approved antiobesity drug |
|
|
364 | (1) |
|
16.10 Bacillus natto probiotics |
|
|
365 | (1) |
|
16.11 Inhibitory effect of fermented skim milk |
|
|
366 | (1) |
|
16.12 Conclusions and perspectives |
|
|
367 | (10) |
|
|
367 | (10) |
|
17 Potential bovine colostrum for human and animal therapy |
|
|
377 | (20) |
|
Maria Giovana Binder Pagnoncelli |
|
|
Fernanda Guilherme Do Prado |
|
|
Juliane Mayara Casarim Machado |
|
|
|
|
|
377 | (1) |
|
17.2 Bovine colostrum composition |
|
|
378 | (4) |
|
17.3 Passive immunity mechanism in human and different animal species |
|
|
382 | (1) |
|
17.4 Bovine colostrum application for human therapy |
|
|
383 | (3) |
|
17.5 Bovine colostrum application for animal therapy |
|
|
386 | (3) |
|
17.6 Conclusions and perspectives |
|
|
389 | (8) |
|
|
389 | (8) |
|
18 Colostrum new insights: products and processes |
|
|
397 | (26) |
|
Alessandra Cristine Novak Sydney |
|
|
|
Maria Carolina De Oliveira Ribeiro |
|
|
Eduardo Bittencourt Sydney |
|
|
Dao Pedro De Carvalho Neto |
|
|
|
|
|
|
397 | (1) |
|
18.2 New insights in colostrum production process and quality control |
|
|
398 | (4) |
|
|
402 | (12) |
|
18.4 Commercial bovine colostrum products |
|
|
414 | (3) |
|
18.5 Conclusion and perspectives |
|
|
417 | (6) |
|
|
418 | (5) |
Index |
|
423 | |